Literature DB >> 1721491

Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases.

H E Schaafsma1, F C Ramaekers, G N van Muijen, H Robben, E B Lane, I M Leigh, E C Ooms, J A Schalken, R J van Moorselaar, D J Ruiter.   

Abstract

The cytokeratin (CK) expression patterns of local, ie, primary or recurrent, high-grade-malignant transitional cell carcinomas (TCCs) of the human urinary tract and autologous lymphogenic and hematogenic metastases (n = 33) were compared. Special attention was paid to CK expression in the tumor invasion front and other areas where tumor-stroma interaction occurred to visualize cell populations with a metastatic phenotype. For this purpose, polypeptide-specific monoclonal antibodies to CKs 4, 7, 8, 10, 13, 14, 16, 17, 18, and 19 were used, employing the immunoperoxidase method. Results show that: 1) An increased expression of CK8 and CK18 is seen in the TCC tumor cells at the interface with peritumoral stroma in the tumor invasion front and with intratumoral stroma ('interface phenomenon'). Other than reflecting a quantitative change, this phenomenon might be explained by unmasking of CK8 and CK18 epitopes occurring in these regions. 2) Although in general the expression of CK13 in local TCC is decreased with increase of histopathologic parameters for progression, ie, grade and stage, an extensive proportion of CK13-positive tumor cells still can be found in some TCCs, even in metastases. 3) Morphologically recognizable types of aberrant differentiation in TCC, i.e., pseudosarcomatous or squamous differentiation and marked loss of differentiation, show altered expression of many of the CKs studied.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721491      PMCID: PMC1886474     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Aberrant expression during two-stage mouse skin carcinogenesis of a type I 47-kDa keratin, K13, normally associated with terminal differentiation of internal stratified epithelia.

Authors:  R Nischt; D R Roop; T Mehrel; S H Yuspa; M Rentrop; H Winter; J Schweizer
Journal:  Mol Carcinog       Date:  1988       Impact factor: 4.784

Review 2.  The major pathways of keratinocyte differentiation as defined by keratin expression: an overview.

Authors:  S Galvin; C Loomis; M Manabe; D Dhouailly; T T Sun
Journal:  Adv Dermatol       Date:  1989

3.  Distribution of cytokeratin polypeptides in epithelia of the adult human urinary tract.

Authors:  H E Schaafsma; F C Ramaekers; G N van Muijen; E C Ooms; D J Ruiter
Journal:  Histochemistry       Date:  1989

4.  Suprabasal 40 kd keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium.

Authors:  K Lindberg; J G Rheinwald
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

5.  Effect of retinoids on hyperproliferation-associated keratins K6 and K16 in cultured human keratinocytes: a quantitative analysis.

Authors:  B Korge; R Stadler; D Mischke
Journal:  J Invest Dermatol       Date:  1990-10       Impact factor: 8.551

Review 6.  Use of keratin antibodies in tumor diagnosis.

Authors:  E B Lane; C M Alexander
Journal:  Semin Cancer Biol       Date:  1990-06       Impact factor: 15.707

7.  Patterns of expression of trichocytic and epithelial cytokeratins in mammalian tissues. I. Human and bovine hair follicles.

Authors:  H W Heid; I Moll; W W Franke
Journal:  Differentiation       Date:  1988       Impact factor: 3.880

8.  Synthesis of cytokeratin 13, a component characteristic of internal stratified epithelia, is not induced in human epidermal tumors.

Authors:  N Kuruc; R E Leube; I Moll; B L Bader; W W Franke
Journal:  Differentiation       Date:  1989-12       Impact factor: 3.880

9.  Antibody markers of basal cells in complex epithelia.

Authors:  P E Purkis; J B Steel; I C Mackenzie; W B Nathrath; I M Leigh; E B Lane
Journal:  J Cell Sci       Date:  1990-09       Impact factor: 5.285

10.  Patterns of expression of keratin 17 in human epithelia: dependency on cell position.

Authors:  S M Troyanovsky; V I Guelstein; T A Tchipysheva; V A Krutovskikh; G A Bannikov
Journal:  J Cell Sci       Date:  1989-07       Impact factor: 5.285

View more
  7 in total

1.  Exocrine pancreatic disorders in transsgenic mice expressing human keratin 8.

Authors:  M L Casanova; A Bravo; A Ramírez; G Morreale de Escobar; F Were; G Merlino; M Vidal; J L Jorcano
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

2.  Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.

Authors:  T A Hembrough; K R Kralovich; L Li; S L Gonias
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

3.  Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins.

Authors:  E Fonseca; J M Nesland; J Höie; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  1997-03       Impact factor: 4.064

4.  Prognostic value of keratin subtyping in transitional cell carcinoma of the upper urinary tract.

Authors:  Cord Langner; Beate J Wegscheider; Peter Rehak; Manfred Ratschek; Richard Zigeuner
Journal:  Virchows Arch       Date:  2004-09-18       Impact factor: 4.064

5.  Expression of cytokeratin-mRNAs in squamous-cell carcinoma and balloon-cell formation of human oesophageal epithelium.

Authors:  A I Viaene; J H Baert
Journal:  Histochem J       Date:  1995-01

6.  Protein and mRNA expression of simple epithelial keratins in normal, dysplastic, and malignant oral epithelia.

Authors:  L Su; P R Morgan; E B Lane
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

7.  Detection of large molecular weight cytokeratin 8 as carrier protein of CA19-9 in non-small-cell lung cancer cell lines.

Authors:  J Fujita; N Dobashi; Y Ohtsuki; Y Ueda; S Bandoh; I Yamadori; J Takahara
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.